MV130 contains different components of whole heat-inactivated gram-positive and -negative bacteria that are involved in upper and lower respiratory infections. These include streptococcus pneumoniae and staphylococcus aureus. Though studies have... Though studies have shown that it reduces the rate of infections in recurrent respiratory tract infections (RRTIs), the complete mechanisms are not fully understood.
- Mechanism
- Curator reviewed
Although the complete mechanisms of action are not known, MV130 is generally thought to generate Th1 immune responses. Developed by Inmunotek S.L., the compound is being assessed as a preventative therapy for the spread and course of SARS-CoV2 infection (NCT04452643), and treatment in mild infection (NCT04363814).
- Also known as
- BACMUNE
- Code names
- MV130
What you can answer from here — as of February 13, 2021
Which companies are running trials of BACTEK-R, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account